NVCR - NovoCure Limited
| Previous Close | 50.72 |
| Open | 50.54 |
| Bid | 47.57 x 800 |
| Ask | 51.36 x 1400 |
| Day's Range | 50.50 - 51.45 |
| 52 Week Range | 26.02 - 56.67 |
| Volume | 245,864 |
| Avg. Volume | 558,458 |
| Market Cap | 4.919B |
| Beta (3Y Monthly) | 2.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.59 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.40 |
- Motley Fool•10 days ago
Insulet and Novocure Are Going Gangbusters
These two medical-device gems posted record results in the first quarter that send their stocks shooting higher.
- Business Wire•13 days ago
Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma
Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to a 45-day public comment period during which the DME MACs will consider feedback from patients, advocacy groups, prescribers and the general public prior to finalizing the LCD. The coverage policy criteria proposed by the DME MACs is generally similar to Optune’s commercial coverage criteria for newly diagnosed glioblastoma (GBM) with the exception of a proposed restriction on beneficiary site of care.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of NVCR earnings conference call or presentation 2-May-19 12:00pm GMT
Q1 2019 Novocure Ltd Earnings Call
- Motley Fool•16 days ago
5 Key Takeaways From NovoCure's Big First-Quarter
Management talks about international expansion, potential FDA approval, and Medicare reimbursement.
Motley Fool•20 days agoNovoCure Limited (NVCR) Q1 2019 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2019.
- Benzinga•21 days ago
The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
- Zacks•21 days ago
NovoCure (NVCR) Reports Q1 Loss, Misses Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 0.00% and -0.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•21 days ago
NovoCure: 1Q Earnings Snapshot
The Saint Helier, Jersey-based company said it had a loss of 13 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- Business Wire•21 days ago
Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018
- Simply Wall St.•23 days ago
The NovoCure (NASDAQ:NVCR) Share Price Is Up 275% And Shareholders Are Boasting About It
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money...
- Business Wire•23 days ago
Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning
- Benzinga•23 days ago
Jim Cramer Weighs In On Canopy Growth, Levi, Twilio And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Entergy Corporation (NYSE: ETR ) is a big winner. He likes the company very much. Novocure Ltd (NASDAQ: NVCR ) is a good company and one ...
- Insider Monkey•27 days ago
Did Hedge Funds Drop The Ball On NovoCure Limited (NVCR) ?
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
- Zacks•28 days ago
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•last month
Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values
Novocure (NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information. In 2018, Novocure made a commitment to put into words its vision, mission and values as part of its corporate objective of investing in its people and culture.
- Simply Wall St.•last month
What You Should Know About NovoCure Limited's (NASDAQ:NVCR) Financial Strength
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$4.4b. However, an important fact which most ignore is: how financially healthy is the business...
- Motley Fool•2 months ago
Why Novocure Stock Fell More Than 10% in March
Despite last month's pullback, shares of this medical device company that's aiming to revolutionize cancer treatment are up 126% over the last year.
- Business Wire•2 months ago
Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.
- Business Wire•2 months ago
Novocure to Report First Quarter 2019 Financial Results
Novocure (NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2019, at 8 a.m. EDT on Thursday, May 2, 2019. The webcast and earnings slides presented during the webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the call.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Apple Hospitality REIT, Superior Energy Services, US Foods Holding, NovoCure, FTS International, and Envestnet — Discovering Underlying Factors of Influence
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Business Wire•2 months ago
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
Novocure (NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma.
- Business Wire•2 months ago
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment
- MarketWatch•2 months ago
Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role
Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president of clinical development, will assume responsibilities for preclinical and clinical development and regulatory affairs effective immediately, and Ely Benaim will join the company as chief medical officer effective April 1, assuming responsibilities for clinical operations, medical affairs and safety. The stock, which is still inactive in premarket trade has soared 67.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 24.6% and the S&P 500 has climbed 16.9%.
- Business Wire•2 months ago
Novocure’s Chief Science Officer Retires after 17 Years of Service
Novocure (NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family. “While this was a difficult decision, it is the right one for my family,” stated Dr. Kirson.
- Business Wire•2 months ago
Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference
Novocure announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019, in New York City.
